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Abstract
Background: Inhibition of procoagulant pathways may improve outcome in sepsis. We examined whether a dual
short-acting thrombin (factor II) and factor X (FX)a inhibitor (SATI) ameliorates sepsis-induced disseminated
intravascular coagulation (DIC) and is organ-protective.
Methods: Escherichia coli were infused for 2 h in 22 anesthetized baboons. The control (CO) group (n = 8) received
sterile isotonic solution only. In the treatment groups, SATI was administered starting 15 minutes after the end of
the bacterial exposure. In the low-dose group (LD-SATI, n = 8), SATI was infused with 75 μg/kg/h for the first hour,
followed by 23 μg/kg/h until the end of the study. In the high-dose SATI group (HD-SATI, n = 6), 225 μg/kg/h was
administered for the first hour followed by continuous infusion of 69 μg/kg/h until termination of the study.
Results: Sepsis-induced DIC was attenuated, as reflected by lower peak thrombin-antithrombin complexes
(threefold) and D-dimer levels (twofold) in both SATI groups compared to the CO. This coincided with strongly
improved cell/organ protection assessed by decreased levels of lactate dehydrogenase (threefold), creatinine
(twofold), aspartate aminotransferase (threefold), and amylase (twofold) compared to the CO group. Anuria, which
started at 8 h in the CO group, was prevented in both SATI groups. Peak interleukin-6 release at 12 h was
prevented in the treatment groups. In both SATI groups, fewer catecholamines were necessary and no bleeding
complications were observed.
Conclusions: Dual inhibition of thrombin and FXa preserved activation of coagulation, protected organ function
and ameliorated inflammation in severe Gram-negative sepsis in baboons. SATI could be a novel therapeutic agent
against sepsis-induced DIC.
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Background
Severe sepsis and septic shock remain a prominent cause
of mortality in hospital, exceeding 30% [1, 2]. Bacterial
invasion not only prompts a potent systemic inflamma-
tory response, but it also results in compelling upregula-
tion of the coagulation system [3–7]. Thus, the majority
of patients with severe sepsis suffer from coagulation
disorders ranging from minor changes in activation
markers to full-blown disseminated intravascular coagu-
lation (DIC) [7, 8].
Experimental studies demonstrate that tissue factor (TF)
expression, in particular on monocytes and endothelial cells
play a key role in the pathogenesis of DIC [7]. TF com-
plexes with factor VII (FVII) and subsequently activates fac-
tor X (FX) and factor IX (FIX) with a strong downstream
effect on thrombin generation [9]. This procoagulant
stimulus in alliance with sustained depression of fibrinolytic
pathways results in disseminated intravascular formation of
microthrombi [5]. Widespread fibrin deposition in the
microcirculation of various organs is closely linked to the
development of multiple organ failure and has been identi-
fied as an important contributor of morbidity and mortality
[5, 10]. For example, Dhainaut et al. reported that mortality
increased from 27% in patients with sepsis without DIC to
43% in those with accompanying DIC [11].
Restoration of anticoagulant pathways by administra-
tion of antithrombin (AT) III, recombinant activated
protein C (APC) and recombinant tissue factor pathway
inhibitor (TFPI) in patients with sepsis without DIC has
not resulted in survival benefits in randomized con-
trolled trials [12–16]. In contrast, ATIII and recombin-
ant APC in patients with overt DIC showed promising
results towards improved outcome [17–19].
Direct thrombin inhibitors such as lepirudin and the pre-
dominant factor Xa inhibitor Danaparoid have been inves-
tigated in endotoxin models. Both substances are sufficient
to hinder activation of coagulation [20, 21]. Until now, no
studies investigated a combined thrombin and FXa inhibi-
tor in severe sepsis. Dual inhibition of thrombin and FXa
in part mimics the natural anticoagulant ATIII, which ef-
fectively inhibits both enzymes [22]. While ATIII binds
thrombin in a 1:1 ratio, direct thrombin and FXa inhibitors
block the active side of the corresponding coagulation fac-
tors and are not dependent on sufficient levels of cofactors
such as heparin [23].
In the current study, we examined the efficacy and
safety of a new potent, short-acting, reversible and select-
ive combined FIIa and FXa inhibitor (short-acting throm-
bosis inhibitor (SATI)) in an established experimental
model of severe Escherichia coli sepsis in baboons [24].
The hypothesis of the current investigation was that the
administration of SATI in severe sepsis will attenuate acti-
vation of coagulation (with consecutive microthrombi for-
mation), diminish DIC and preserve organ function.
Methods
The experimental protocol was approved by the Institu-
tional Animal Care use Committee at Free State University
Bloemfontein, South Africa (number 03/2010). All experi-
ments were performed under the conditions described in
the Guide for the Care and Use of Laboratory Animals as
defined by the National Institutes of Health.
Twenty-two healthy male Chacma baboons of the strain
Papio ursinus, with a median weight of 18.1 (16.5–22.3)
kg and aged between 3 and 10 years were included in the
current study. The animals were quarantined for 3 months
prior to the study. The primates were fasted overnight be-
fore experiments, with free access to water.
Premedication, anesthesia and instrumentation of the
animals
Premedication of the baboons was performed by intra-
muscular injection of 6–8 mg/kg body weight (BW)
ketamine hydrochloride (Ketalar®, Pfizer, Vienna, Austria).
After placing the animal in the supine position, the right
cubital vein was cannulated and anesthesia was induced
using 5 mg/kg BW sodium pentobarbital (Sandoz GmbH,
Kundl, Austria) and maintained by continuous infusion of
0.8 mg/kg/h sodium pentobarbital, 0.8 μg/kg/h, sufentanil
(Janssen, Vienna, Austria), and 1 mg/kg/h rocuronium
(Organon, Oss, Netherlands).
Following endotracheal intubation the animals were
ventilated in volume-controlled mode using a tidal volume
of 6–8 ml/kg and a respiratory rate of 18–20 breaths/
minute in order to maintain an arterial pressure of CO2
at 35–45 mmHg (Evita 2, Dräger, Lübeck, Germany).
The fraction of inspired oxygen was set at 0.30 and ad-
justed if necessary according to blood gas analyses.
Body temperature was kept at 37 °C.
Three catheters were placed using the Seldinger tech-
nique: (1) for blood pressure monitoring and blood sam-
pling a catheter was inserted into the right femoral artery;
(2) the cephalic vein was used for fluid therapy and ad-
ministration of SATI; and (3) a Swan-Ganz catheter
(Edwards Lifesciences, Irvine, CA, USA) was inserted
via the femoral vein for measurement of central venous
pressure (CVP), pulmonary arterial pressure and, pulmon-
ary artery occlusion pressure (PAOP), and hemodynamic
variables such as cardiac index (CI), systemic vascular re-
sistance index (SVRI) and pulmonary vascular resistance
index (PVRI). A transurethral catheter was placed to
quantify urine output at baseline, and at 2-h intervals for
8 h, followed by 4-h intervals for 24 h).
Experimental design
After a stabilization period, 5 × 106 colony-forming units
(CFU)/kg E. coli O111:K58(B4):H-(ATCC 33780) were
infused under continuous stirring over a 2-h period via a
motor-pump as previously described [25] (Fig. 1).
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Ringer’s solution (Fresenius-Kabi GmBH, Bad Homburg,
Germany) of at least 5 ml/kg/h was infused to maintain
mean arterial blood pressure (MAP) at >70 mmHg and
CVP and PAOP at >5 mmHg. If these target values were
not established, higher rates of Ringer’s solution or nor-
adrenalin (or if necessary adrenalin) were administered.
Antibiotics were not used.
To investigate the optimal dose for efficacy and safety,
two treatment regimens were evaluated: for the lower
dose a plasma concentration was selected that led to a
prothrombin time (PT) prolongation of 1.4 in healthy
animals. This concentration was chosen, because it re-
sulted in a significant reduction in thrombus weight of
about 50% in an arteriovenous shunt thrombosis model
in rats, which has previously been used for predictions
of concentration in the setting of acute thrombosis. As
expected, a threefold higher concentration led to approxi-
mately 80% reduction in thrombus weight, but it did not
lead to a significant increase in bleeding time. Thus, these
two doses were chosen to investigate whether the lower
dose is as efficacious as in acute arterial thrombosis sce-
narios and whether the higher dose would have even more
efficacy with an acceptable bleeding profile.
At 15 minutes after completion of the bacterial infu-
sion the animals were randomly assigned to one of three
groups. The control (CO) group (n = 8) received a crys-
talloid solution as vehicle (Ionosteril, Fresenius-Kabi
GmBH, Bad Homburg, Germany). The treatment groups
received either low-dose SATI (LD-SATI) or high-dose
SATI (HD-SATI). The LD-SATI group (n = 8) started
with 75 μg/kg/h for the first hour followed by 23 μg/kg/h
until the end of the study. In the HD-SATI group (n = 6),
225 μg/kg/h was administered for the first hour followed
by continuous infusion of 69 μg/kg/h until the end of the
study. SATI was dissolved in 50 ml of vehicle. At 24 h
after the start of the bacterial infusion, the animals were
killed by an intravenous (i.v.) bolus injection of 100 mg/kg
pentobarbital followed by 10 ml (1 mmol/ml) potassium
chloride.
Blood sampling
Baseline blood samples for blood gas analysis, blood cell
count and clinical chemistry analysis were obtained after
1 h, 2 h and then at every 2 h within the first 8 h,
followed by sampling every 4 h until the end of the experi-
ment (24 h) (Fig. 1). Blood cell counts were determined by
a Coulter T890 counter (Coulter Electronics Inc., Hialeah,
FL, USA). Coagulation analyses were performed in the
blood collected in 3-ml tubes containing 0.3 ml buffered
3.2% trisodium citrate, giving a volume ratio of 1 + 9
(Vacuette; Greiner Bio-One, Linz, Austria). Blood was
centrifuged immediately at 2000 g for 10 minutes to obtain
plasma, which was stored at –80 °C until analysis.
Coagulation tests
The coagulation tests were performed according to the
manufacturer’s instructions: antithrombin (AT) (AssayMax
human Antithrombin III ELISA; AssayPro, St. Charles,
MO, USA); D-dimer (Asserachrom D-Dimer ELISA,
Diagnostica Stago, Taverny, France); fibrinogen (Human
Fibrinogen ELISA, ICL, Portland, USA); PAI-1 antigen
(Technozym ELISA, Cryopep, France); activated protein C
(human activated Protein C ELISA, Wuhan USCNK, Hous-
ton, USA); thrombin-antithrombin-complexes (Enzygnost
TAT micro, ELISA, Siemens, Marburg, Germany); tissue-
plasminogen-activator activity (Technozym ELISA t-PA,
Technoclone, Vienna, Austria); tissue factor pathway
inhibitor (Quantikine human TFPI ELISA, R&D Systems,
Minneapolis, USA), thrombin activated fibrinolysis inhibi-
tor (Zymotest TAFI Antigen; Hyphen, Neuville-sur-Oise,
France) and thrombomodulin (Diagnostica Staro, Taverny,
France).
Inflammation markers
Lipopolysaccharide binding protein (LBP), interleukin
(IL)-6, and IL-10 were determined using ELISA assays
and performed on Immulite® 1000 (Siemens Healthcare,
Erlangen, Germany). Tumor necrosis factor-α (TNF-α)
was measured by ELISA kits (Bender MedSystems,
Fig. 1 Study protocol. SATI short-acting thrombosis inhibitor
Schöchl et al. Critical Care  (2017) 21:51 Page 3 of 12
Vienna, Austria) according to the manufacturer’s
instructions.
Blood gases and chemistry
Arterial and venous blood gases were measured (Radiometer
ABL 330, Copenhagen, Denmark). Renal (urea, creatinine,
uric acid), liver (aspartate-Aminotransferase (AST), alanine-
aminotransferase (ALT) and bilirubin) and pancreas pa-
rameters (amylase, lipase) and cell damage parameters
(lactate dehydrogenase (LDH) were analyzed using the
Sysmex XE-2100 (Sysmex, Kobe, Japan).
Statistical analyses
To investigate group differences and changes in organ
function parameters due to the intervention in an overall
analysis, we performed repeated measures analysis of vari-
ance (ANOVA) with time as a within-subjects-factor and
group as a between-subjects-factor for each parameter.
The start of SATI administration was chosen as the refer-
ence time point for the comparisons between the CO and
treatment groups. Post hoc analyses were conducted using
the Scheffé test. Analysis of differences was performed
separately for each time point using the t test for inde-
pendent samples (Bonferroni-corrected). For categorical
variables, the chi square test was used. P values <0.05 were
considered statistically significant. All statistical calcula-
tions were performed using commercially available statis-
tical software (SPSS 23.0) and figures were created using
GraphPad Prism 5.03. Data are expressed as mean and
standard deviation (SD) or median and interquartile
range.
Results
Of the 22 baboons, 20 survived until the end of the experi-
ment; the two deaths were encountered in the LD-SATI
group. Importantly, no severe and/or life-threating
bleeding complications (e.g. mucosal bleeding, bleeding
from catheter insertion sites or hematuria) were observed
either in the CO group or in either of the SATI treatment
groups.
Sepsis-related coagulopathy
The bacterial challenge resulted in strong procoagulant
activation indicated by high thrombin-anti-thrombin
(TAT) complexes in the CO group. SATI administration
abolished TAT complex formation (p < 0.0001) in the
treatment groups compared to the CO group (peak,
threefold higher), and significantly attenuated fibrinogen
consumption in the HD-SATI group (HD-SATI vs the
CO group, p < 0.02). All animals developed severe
thrombocytopenia after infusion of E. coli, without any
significant differences between the CO group and the
two SATI groups (Fig. 2a-c).
ATIII significantly decreased over time in all groups
(p < 0.0001), but only LD-SATI preserved ATIII con-
sumption (p ≤ 0.02). APC increased significantly until
the end of the experiment (p < 0.0001). HD-SATI ad-
ministration resulted in lower APC values compared
to the CO group (time point 8 h from baseline (TP 8),
p < 0.014). Soluble Thrombomodulin (sTM) strongly in-
creased over the observation period without significant
differences between groups (data not shown). In the
CO group, TFPI increased significantly until the end of
the experiment (p < 0.0001). Animals in both treatment
groups had lower TFPI concentrations compared to
those in the CO group (both p < 0.0001). In particular,
HD-SATI abolished upregulation of TFPI almost com-
pletely (Fig. 3a-c).
D-Dimers significantly increased over time in all groups
reaching the highest level at TP 20 (p < 0.0001). Significant
differences between the CO and LD-SATI groups (p ≤
0.005) and the HD-SATI group (p ≤ 0.001) were detected.
Fig. 2 a-c Thrombin-antithrombin complexes (TAT), fibrinogen (Fib) concentration and platelet count starting from baseline (time point 0 h) until
the end of the experiment (time point 24 h). Arrow represents the duration of E. coli infusion (first 2 h). White control group (CO), light gray low-dose
short-acting thrombosis inhibitor (LD-SATI), dark gray high-dose (HD)-SATI. SATI prevented TAT formation and consumption of fibrinogen but the
decrease in platelet count was unaffected. a TAT. b Fibrinogen CO vs LD-SATI ***p < 0.001, **p < 0.01, *p < 0.05; CO vs HD-SATI ###p < 0.001,
##p < 0.01, #p < 0.05; no indication = not significant. Two-factor analysis of variance was used for between-group comparisons. Gray arrow represents
the time of the E. coli infusion
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D-dimers at TP 12 were twofold higher in the CO com-
pared to the treatment groups. HD-SATI appeared to be
more efficient in attenuating D-Dimer production com-
pared to LD-SATI. Plasminogen activator inhibitor 1 anti-
gen (PAI-1) significantly increased over the observation
period in all groups reaching the highest levels at TP 12.
HD-SATI treatment resulted in significantly lower levels
of PAI-1 compared to control (p = 0.03). Thrombin-
activated fibrinolysis inhibitor antigen (TAFI) strongly in-
creased in the CO group reaching the highest level at TP
16 (p < 0.0001). TAFI activation was sufficiently attenuated
(p < 0.0001) in both SATI groups (Fig. 3d-f).
Sepsis-induced organ damage
Oxygenation significantly deteriorated over the observation
period in all groups as indicated by a steady decrease in
the ratio of arterial oxygen partial pressure to fractional
inspired oxygen (paO2/FiO2) ratio (p < 0.0001) (Fig. 4a)
without significant differences between groups.
All animals in the CO group were anuric after TP 8,
while urine production did not stop in any of the SATI-
treated baboons. Both creatinine and urea significantly
increased over time in all groups. However, creatinine
was twofold higher in the CO group compared to both
SATI treatment arms at TP 24 (p < 0.0001). Similarly,
urea was twofold higher in the CO compared to the
HD-SATI group (p ≤ 0.03) (Fig. 4b, c).
Treatment with LD-SATI and with HD-SATI lowered
circulating AST threefold compared to CO at 24 h (p <
0.001). Amylase increased significantly in the course of
the study (p < 0.005); SATI treatment (regardless of the
dose) significantly abolished release of amylase (p < 0.05)
compared to CO. LDH strongly increased over time in
all groups (p < 0.0001). SATI treatment in both dose groups
resulted in threefold lower LDH release compared to the
CO (both p < 0.0001), (Fig. 4 d-f).
Inflammation parameters after E. coli administration
In all groups, bacterial infusion caused a strong increase
in circulating inflammatory cytokines. TNF-α and IL-10
peaked, prior to treatment, 2 h after the start of bacterial
infusion without differences among groups. IL-6 signifi-
cantly changed over time (p < 0.001). The highest concen-
tration of IL-6 was reached 10 h after termination of the
bacterial infusion (TP 12) in the CO group. In contrast,
maximum IL-6 concentrations were measured at TP 8 in
the LD-SATI group and at TP 6 in the HD-SATI group,
respectively. SATI treatment in both arms significantly at-
tenuated the magnitude of IL-6 release compared to CO
(both p < 0.0001) (Fig. 5a-c).
Fig. 3 a-f Natural coagulation inhibitors, natural fibrinolysis inhibitors and D-Dimers starting from baseline (time point 0 h) until the end of the
experiment (time point 24 h). Arrow represents the duration of E. coli infusion (first 2 h). White control group (CO), light gray low-dose short-acting
thrombosis inhibitor (LD-SATI), dark gray high-dose (HD)-SATI. a Antithrombin III (AT III) ; b activated protein C (APC); c tissue factor pathway inhibitor
(TFPI); d plasminogen activator inhibitor 1 (PAI-1); e thrombin-activated fibrinolysis inhibitor antigen (TAFI); f D-Dimer. CO vs HD-SATI ***p < 0.001,
**p < 0.01, *p < 0.05; CO vs HD-SATI ###p < 0.001, ##p < 0.01, #p < 0.05; no indication = not significant. Two-factor analysis of variance was used
for between-group comparisons. Gray arrow represents the time of E. coli infusion
Schöchl et al. Critical Care  (2017) 21:51 Page 5 of 12
Temperature was not different between the groups
(data not shown). Similarly, circulating LBP concentra-
tions were not different between the groups over the ob-
servation period.
Hemodynamic response to sepsis
MAP, CI, SVRI and PVRI significantly changed over
time (all p < 0.03) (Table 1). Administration of SATI led
to higher CI, and lower SVRI and PVRI. Base excess
(BE) significantly decreased over the observation period
in all groups (p < 0.0001). However, SATI administration
resulted in significantly improved BE in both treatment
arms compared to the CO group from TP 8 until the
end of the experiment (p < 0.01). Noradrenaline was re-
quired to maintain MAP >70 mmHg in seven out of
eight animals in the CO group, compared to three out of
eight in the LD-SATI group and one out of six in the
HD-SATI group (p < 0.03). Nevertheless, two baboons
Fig. 5 a-f Inflammatory cytokines starting from baseline (time point 0) until the end of the experiment (time point 24 h). Arrow represents the
duration of E. coli infusion (first 2 h). White control group (CO), light gray low-dose short-acting thrombosis inhibitor (LD-SATI), dark gray high-dose
(HD)-SATI. SATI prevented increase in interleukin 6 (IL-6) release in both treatment groups. CO vs LD-SATI group ***p < 0.001, **p < 0.01, *p < 0.05;
CO vs HD-SATI # # #p < 0.001, # #p < 0.01, #p < 0.05; no indication = not significant. Two-factor analysis of variance was used for between-group
comparisons. Gray arrow represents the time of E. coli infusion. TNF-α tumor necrosis factor alpha, AT III antithrombin III, APC active protein C,
TFPI tissue factor pathway inhibitor, TAFI thrombin-activated fibrinolysis inhibitor antigen, PAI-I plasminogen activator inhibitor 1 antigen
Fig. 4 a-f Organ function starting from baseline (time point 0 h) until the end of the experiment (time point 24 h). Arrow represents the duration
of E. coli infusion (first 2 h). White control group (CO), light gray low dose short-acting thrombosis inhibitor (LD-SATI), dark gray high-dose (HD)-SATI).
LDH lactate dehydrogenase, AST aspartate aminotransferase. a Oxygenation ratio (FiO2/paO2); b creatinine; c urea; d aspartate-amino-transferase (AST);
e amylase; f lactate-dehydrogenase (LDH). CO vs HD-SATI ***p < 0.001, **p < 0.01, *p < 0.05; CO vs HD-SATI ###p < 0.001, ##p < 0.01, #p < 0.05.
Two-factor analysis of variance was used for between-group comparisons. Gray arrow represents the time of E. coli infusion
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died in the LD-SATI group: one after 16 h and one after
19 h due to hemodynamic failure but not to bleeding
complications.
Blood cell count after E. coli infusion
All animals developed anemia and neutropenia after in-
fusion of E. coli (Table 2). No significant differences were
observed between the CO and the SATI groups.
Discussion
This is the first study investigating the effect of dual in-
hibition of thrombin and activated FX in a non-human
primate model of severe Gram-negative sepsis. Post-
treatment with SATI starting 2 h and 15 minutes after
the initiation of sepsis blocked thrombin and factor X-
mediated activation of coagulation and maintained natural
inhibitors such as ATIII and APC. Moreover, profibrinoly-
tic pathways were preserved in particular in those animals
that received HD-SATI. Most importantly, treatment with
SATI, regardless of the dose, strongly attenuated sepsis-
induced organ injury reflected by the reduced release of
organ-specific enzymes and even prevented anuria, which
developed after 8 h. The results of the current study indi-
cate that dual inhibition of thrombin and FXa by SATI is
capable of attenuating the severity of DIC and counteracts
sepsis-induced organ dysfunction. Furthermore, SATI
abolished the late inflammatory response as indicated by
diminished release of circulating IL-6.
We used a baboon model, which closely recapitulates
early events in human sepsis such as hyperdynamic re-
sponse in the acute phase, even with adequate fluid resusci-
tation [24–26]. The bacterial challenge was severe enough
to provoke a massive inflammatory response, strong activa-
tion of coagulation and sustained organ damage, but
allowed the majority of animals to survive for 24 h; only
two baboons died before completion of the experiment.
At the end of the bacterial infusion, all groups had a
similar septic phenotype: high inflammatory response,
hemodynamic instability and strong upregulation of
procoagulant pathways.
The protracted infusion of E.coli strongly increased
thrombin generation as indicated by a very high concen-
tration of TAT complexes in the CO group. ATIII binds
thrombin in a 1:1 ratio leading to formation of TAT
[27]. In contrast, SATI treatment robustly reduced active
thrombin binding to ATIII, resulting in lower TAT via
two modalities. On one hand SATI blocks the active site
of thrombin and consequently inhibits binding to ATIII.
On the other hand it can be partly related to the reduced
thrombin production by SATI via blockade of Xa activity
(dual-action SATI concept). Thus, ATIII decreased sig-
nificantly more in the CO group compared to both SATI
groups due to higher consumption by free thrombin,
consequently leading to stronger elevation in TAT in the
CO group. Other inhibitors such as APC and TFPI in-
creased to a greater extent in the CO group compared
to the SATI groups up to the end of the experiment. As
mentioned, this effect could be explained by the fact that
SATI blocks the active thrombin site, consequently hin-
dering binding on TM. Thus, activation of protein C is
downregulated by SATI, which led to a higher concen-
tration of APC in the CO group.
In the present study, the marked increase in PAI-1 was
significantly ameliorated by HD-SATI. High concentra-
tions of inflammatory cytokines such as TNF-α and IL-1
provoke release of PAI-1 into the bloodstream, causing
sustained inhibition of thrombolysis [28]. In experimental
and clinical studies, high PAI-1 has been strongly associ-
ated with poor outcome in severe sepsis [29, 30].
Additionally, we observed strong upregulation of TAFI
in the CO group, which further hinders lysis. This effect
was in part counteracted by high APC in the CO group,
which in turn inactivates PAI-1. D-dimer elevation in
the CO group could result from a sustained increase in
fibrin formation (related to high thrombin availability)
rather than being per se a marker of upregulated lysis.
Interestingly thrombocytopenia was not different be-
tween the groups. This is a remarkable finding in the light
that SATI robustly abolished thrombin generation as indi-
cated by significantly lower TAT. A possible explanation
for this observation is that this severe life-threatening sep-
sis resulted in sustained upregulation of platelet action,
which in turn caused pronounced thrombocytopenia inde-
pendent of therapeutic intervention.
Hemodynamic instability and organ dysfunction is a
common issue in severe sepsis and septic shock [10].
Intravascular fibrin formation results in limited nutrient
delivery to vital organs and consecutive end-organ damage.
In particular, tissues with high oxygen demand such as the
kidneys are susceptible to compromised end-organ perfu-
sion [31]. The BE was significantly lower in the CO group
compared to both SATI treatment arms, which might
suggest improved microvascular blood flow. While all
CO animals stopped urine production after the first
8 h, remarkably, diuresis in both SATI groups was main-
tained until the end of the experiment. The sepsis-induced
organ dysfunction in our study closely meets the most re-
cent definition of sepsis [32]. Over the study course, the
lung, liver, kidney and pancreas function deteriorated. The
life-threatening organ failure observed in the CO group
was significantly improved in baboons treated with SATI.
In particular, HD-SATI preserved organ function. It is im-
portant to note that, in both SATI groups compared to the
CO, fewer catecholamines were necessary to maintain
MAP >70 mmHg.
Several randomized controlled studies have been con-
ducted using natural anticoagulants such as ATIII [13, 14],
recombinant human APC [12, 16], recombinant human
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TFPI [12, 15] or recombinant human TM [33] in patients
with sepsis. Those drugs reduced the hemostatic abnor-
malities in sepsis but did not improve survival [34]. How-
ever, on post-hoc subgroup analysis restricted to those
patients with overt DIC, there were survival benefits in
both the Kybersept study and the PROWESS trial [17, 18].
This strongly implies the need for a more homogenous
stratification of patients with sepsis into those with overt
DIC and those with sepsis but non-overt DIC. Patients
with established DIC could benefit from treatment with
anticoagulants such as ATIII or APC. Our data provide
evidence that dual inhibition of both thrombin and FXa
robustly ameliorates organ dysfunction, most likely by
improving microvascular nutrient blood flow based on
diminished intravascular fibrin formation.
Another important finding of the current study is that
SATI treatment was highly effective in preventing the
progression of DIC but there were no signs that it pro-
voked any severe bleeding events, even in the HD-SATI
group. This is in strong contrast to studies testing thera-
peutic administration of ATIII and APC, which led to
life-threatening bleeding complications [12, 13]. Giardino
et al. confirmed that compared to selective inhibition
alone, dual inhibition of thrombin and FXa exerts a super-
ior antithrombotic efficacy with a tendency toward dimin-
ished bleeding [22].
The bacterial infusion provoked a potent release of ini-
tial inflammatory cytokines prior to the onset of treat-
ment. Thus, SATI could not have meaningful effect on
the time course and magnitude of TNF-α and IL-10,
which peaked at the end of the bacterial challenge, long
before the start of treatment. IL-6 release occurs later
than that of TNF-α and IL-10; however, the pattern of
production is somewhat different in various models [35].
Both SATI groups were effective in attenuating late IL-6
release in the bloodstream. IL-6 has been shown to be,
at least in part, under the control of the initial TNF-α
release [36]. Considering that TNF-α release prior to the
SATI treatment was not affected, we assume that SATI
per se has a direct effect on IL-6 neo-synthesis. Alternatively,
the observed effect could be a consequence of diminished
availability of thrombin, which has strong pro-inflammatory
properties [4].
Limitation
Due to the limited observation period, our study does not
provide any relevant outcome information on the efficacy
of SATI at later stages. Early empiric antibiotic treatment
is an essential part of initial treatment of patients with
sepsis [10]. In the current short-term study, we did not
use any additional antibiotic therapy, which could poten-
tially have influence on the time course of sepsis-related
organ damage. However, SATI treatment according to our
protocol was effective in improving sepsis-related organ
injury.
The duration of the study was too short to completely
rule out substantial bleeding complications at a later stage.
However, even in the HD-SATI group relevant bleeding
episodes were not observed, including external bleeding
and mucosa or gastrointestinal bleeding, which would have
been apparent after harvesting the organs post mortem.
Two animals in the LD-SATI group died due to
hemodynamic decompensation. However, it has to be
noted that the study was not powered to show any sur-
vival differences between groups.
Conclusion
SATI treatment diminished thrombin formation and pre-
served anticoagulant and fibrinolytic pathways. This effect
coincided with an effective and robust reduction in severe
sepsis-induced organ injury in both SATI treatment groups.
Moreover, dual inhibition of thrombin and aFX with SATI
strongly ameliorated late inflammation in baboons with
sepsis.
Key messages
 Bacterial invasion prompts a compelling upregulation
of the coagulation system and inhibits anticoagulant
and fibrinolytic pathways, which results in widespread
microvascular fibrin deposition
 Dual inhibition of activated FII and activated FX
(SATI) diminishes thrombin formation and preserves
anticoagulant and fibrinolytic pathways
 SATI administration strongly ameliorates IL-6 release
in severe sepsis
 SATI robustly attenuates sepsis-induced organ
damage and protects organ function
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